The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Metal-Based Anti-inflammatory Drugs with High Efficacy and Low Side-Effects. Non-steroidal anti-inflammatory drugs (NSAIDs) have widespread human and veterinary applications for the treatment of arthritis and other inflammatory diseases, but their utility is limited by often severe gastrointestinal, renal and cardiac side-effects. The recently heralded COX-2 inhibitors have not lived up to their expectations in terms of efficacy and side-effects, therefore, there is a need to develop new potent ....Metal-Based Anti-inflammatory Drugs with High Efficacy and Low Side-Effects. Non-steroidal anti-inflammatory drugs (NSAIDs) have widespread human and veterinary applications for the treatment of arthritis and other inflammatory diseases, but their utility is limited by often severe gastrointestinal, renal and cardiac side-effects. The recently heralded COX-2 inhibitors have not lived up to their expectations in terms of efficacy and side-effects, therefore, there is a need to develop new potent, but safer, NSAIDs. This project is aimed at using the results from new lead compounds to design NSAIDs with much greater efficacy and much less side effects than those currently available.Read moreRead less
Oral Insulin Delivery facilitated by Enteric Coating using Dense Gas Technologies. Insulin dependant diabetes is a rapidly growing disease. The current method for insulin delivery to the patient is by injection, which is inconvenient. Oral delivery of insulin is a more acceptable method. It is proposed to develop a dense gas technique to coat insulin with a pH sensitive polymer to protect it from the acidic environment of the stomach. Insulin can then be released at the high pH of the intestin ....Oral Insulin Delivery facilitated by Enteric Coating using Dense Gas Technologies. Insulin dependant diabetes is a rapidly growing disease. The current method for insulin delivery to the patient is by injection, which is inconvenient. Oral delivery of insulin is a more acceptable method. It is proposed to develop a dense gas technique to coat insulin with a pH sensitive polymer to protect it from the acidic environment of the stomach. Insulin can then be released at the high pH of the intestine when the polymer is dissolved. Particle size control is feasible by dense gas processes by manipulating operating parameters. Advantages include low residual solvent and manufacture at ambient temperatures.Read moreRead less
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE0668493
Funder
Australian Research Council
Funding Amount
$230,000.00
Summary
Characterising particulate laden flow in the lung airways: from drug delivery to primary anthropogenic sources. Facilities will provide infrastructure at Monash University and University of Sydney to continue the collaboration enhancing excellence in an exciting application of fluidics research, supporting the highest level of graduate training, providing innovative tools for industry and promoting industrial collaborations. The infrastructure is unique and will create international funding and ....Characterising particulate laden flow in the lung airways: from drug delivery to primary anthropogenic sources. Facilities will provide infrastructure at Monash University and University of Sydney to continue the collaboration enhancing excellence in an exciting application of fluidics research, supporting the highest level of graduate training, providing innovative tools for industry and promoting industrial collaborations. The infrastructure is unique and will create international funding and collaborative opportunities to support research and postgraduate training. The equipment will add value to existing infrastructure to enhance understanding of particulate flow with the paradoxical outcomes of improving drug deposition in respiratory delivery and of minimising anthropogenic particular deposition for better therapeutic and health outcomes.Read moreRead less
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE0560661
Funder
Australian Research Council
Funding Amount
$245,300.00
Summary
Particulate Characterisation for Pharmaceutical and Engineering Applications. The aim of this proposal is to establish joint facilities between the University of Sydney, Monash University and UNSW for the characterization of surface properties and particle sizes of pharmaceutical aerosols and industrial powders. Such knowledge is important for controlling aerosol production and delivery of drug particles to the lungs. This will have a significant benefit to the pharmaceutical industry and patien ....Particulate Characterisation for Pharmaceutical and Engineering Applications. The aim of this proposal is to establish joint facilities between the University of Sydney, Monash University and UNSW for the characterization of surface properties and particle sizes of pharmaceutical aerosols and industrial powders. Such knowledge is important for controlling aerosol production and delivery of drug particles to the lungs. This will have a significant benefit to the pharmaceutical industry and patients requiring aerosol treatment. Further, the proposed facilities will enhance research in complex particulate processes and modelling, functional nanomaterials, and soft sensor development, thus keeping Australia at the forefront of powder research into various high value adding particulate areas.Read moreRead less
Engineering of co-crystal drug molecules for pharmaceutical aerosols. This project will enable Australia to become a world leader in treatment of respiratory diseases. The Australian financial burden of respiratory diseases is currently estimated as $900m with significant impact on infrastructure (through regular clinical visits, hospitalisation and workforce loss). The global market for the treatment of COPD is currently $32 billion and is expected to increase significantly by 2010. The positio ....Engineering of co-crystal drug molecules for pharmaceutical aerosols. This project will enable Australia to become a world leader in treatment of respiratory diseases. The Australian financial burden of respiratory diseases is currently estimated as $900m with significant impact on infrastructure (through regular clinical visits, hospitalisation and workforce loss). The global market for the treatment of COPD is currently $32 billion and is expected to increase significantly by 2010. The positioning of an Australian research as a world leader in the development of new treatments will have significant national benefit, whilst the sector will benefit for scientific advancements that arise during this project.Read moreRead less
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE0775720
Funder
Australian Research Council
Funding Amount
$100,000.00
Summary
State-of-the-art high resolution thermal analysis suite for the life and material sciences. The facility, unique in Australia, will ensure that Australia will retains in a leading position in these research fields, will provide a basis to be competitive in international funding and support postgraduate training. The acquired equipments will strengthen the already existing infrastructures, enhancing understanding of intrinsic physico-chemical characteristic of various materials, to benefit the co ....State-of-the-art high resolution thermal analysis suite for the life and material sciences. The facility, unique in Australia, will ensure that Australia will retains in a leading position in these research fields, will provide a basis to be competitive in international funding and support postgraduate training. The acquired equipments will strengthen the already existing infrastructures, enhancing understanding of intrinsic physico-chemical characteristic of various materials, to benefit the community such as characterising functional nanomaterials for high-tech technologies and use of inhalation aerosol drug delivery to benefit patients with respiratory diseases for an improved therapeutic and health outcome.Read moreRead less
Dispersion of Pharmaceutical Powders as Aerosols for Inhalation. The detrimental environmental effects of chlorofluorocarbons (CFC) have led to an urgent need of a replacement for the existing CFC propellant driven medical inhalers. Generation of aerosols from dry powders has enormous potential as an alternative for delivery of drugs to the lung. The aims of the proposed research are to investigate specifically the powder surface properties and the orperating conditions on the dispersion of po ....Dispersion of Pharmaceutical Powders as Aerosols for Inhalation. The detrimental environmental effects of chlorofluorocarbons (CFC) have led to an urgent need of a replacement for the existing CFC propellant driven medical inhalers. Generation of aerosols from dry powders has enormous potential as an alternative for delivery of drugs to the lung. The aims of the proposed research are to investigate specifically the powder surface properties and the orperating conditions on the dispersion of powders as aerosols for inhalation. The knowledge gained will acclerate the design of better powder aerosols, thus benefiting patients suffering from respiratory and systemic diseases.Read moreRead less
Mannitol Powders for Assessment of Asthma in Children. A successful conclusion of this project will enable Australia to become a world leader in childhood asthma assessment. The availability of an objective diagnostic test for early detection of asthma would assist formulating early treatment strategies at this crucial stage in the progression of the disease, improving the quality of life of asthma sufferers in their early years. The Australian pharmaceutical sector will benefit through the ab ....Mannitol Powders for Assessment of Asthma in Children. A successful conclusion of this project will enable Australia to become a world leader in childhood asthma assessment. The availability of an objective diagnostic test for early detection of asthma would assist formulating early treatment strategies at this crucial stage in the progression of the disease, improving the quality of life of asthma sufferers in their early years. The Australian pharmaceutical sector will benefit through the ability to develop proprietary formulations targeted towards taking advantages of the scientific knowledge on pharmaceutical powders and aerosols. The mannitol testing is environmental friendly as powder aerosol delivery does not require any harmful organic solvents to operate.Read moreRead less
Engineering a delivery device and development of a novel formulation for chronic obstructive pulmonary disease and cystic fibrosis. This project will position Australia to become one of the world leaders in the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and other chronic respiratory diseases. The financial burdens of COPD and CF come to at least $900 million a year in Australia alone. These diseases have significant impact on patients and the health system th ....Engineering a delivery device and development of a novel formulation for chronic obstructive pulmonary disease and cystic fibrosis. This project will position Australia to become one of the world leaders in the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and other chronic respiratory diseases. The financial burdens of COPD and CF come to at least $900 million a year in Australia alone. These diseases have significant impact on patients and the health system through regular clinical visits, hospitalisation and employment downtime. The global market for the treatment of COPD is currently more than $8 billion and is expected to increase substantially. The positioning of an Australian pharmaceutical company at the forefront of COPD/CF treatment will have significant national benefits for patients, the health system, and research infrastructure in the field.Read moreRead less
Blood component interactions with polysaccharide biomaterials for vascular applications. Heart disease is the major killer of people in Australia and the Western world. It is due mainly to the blockage of vessels supplying the muscle of the heart with blood and nutrients, which can be replaced or by-passed but the supply of native vessels in the body is limited. Tissue engineering laboratories have been trying to develop blood vessels for this use for many years without significant success. T ....Blood component interactions with polysaccharide biomaterials for vascular applications. Heart disease is the major killer of people in Australia and the Western world. It is due mainly to the blockage of vessels supplying the muscle of the heart with blood and nutrients, which can be replaced or by-passed but the supply of native vessels in the body is limited. Tissue engineering laboratories have been trying to develop blood vessels for this use for many years without significant success. This application plans to understand the molecular signals contained within the sugar sequences used in a commonly used biomaterial chitosan that may be used in the construction of synthetic vascular grafts. If we can understand how blood cells interact with this biomaterial, we may be able to develop a blood vessel in the laboratory.Read moreRead less